Декслансопразол МВ в лечении гастроэзофагеальной рефлюксной болезни

Декслансопразол МВ является R-энантиомером лансопразола и в настоящее время является единственным ингибитором протонного насоса с новой технологией доставки Dual Delayed Release. Фармакокинетика препарата показывает два пика высвобождения в двенадцатиперстной и тонкой кишках; антисекреторное действие показано в дозах 30 и 60 мг, удержание внутрижелудочного рН > 4 более 16,5 ч/сут независимо от времени приема. В клинических исследованиях показано, что декслансопразол МВ обладает высокой эффективностью в заживлении эрозивного эзофагита и контроле симптомов у пациентов с неэрозивной рефлюксной болезнью, поддерживает ремиссию при длительном применении. Эффективен в улучшении симптомов ночной изжоги, связанной с ГЭРБ, при нарушении сна. Декслансопразол МВ имеет аналогичный профиль безопасности и побочных эффектов с лансопразолом.

1. Moayyedi P., Santana J., Khan M., Preston C., Donnellan C. WITHDRAWN: Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2011; 2: CD003244.

2. Katz P.O., Scheiman J.M., Barkun A.N. Review article: Acid-related disease – What are the unmet clinical needs? Aliment Pharmacol Ther. 2006; 23(Suppl 2): 9–22.

3. Ruigómez A., Johansson S., Wernersson B., Fernández C.O., García R.L.A.. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012; 47(7): 751-61.

4. Bell N.J., Burget D., Howden C.W., Wilkinson J., Hunt R.H. Appropriate acid suppression for the management of gastro‐oesophageal reflux disease. Digestion. 1992, 51(Suppl. 1): 59–67.

5. Hunt R.H. Review article: the unmet needs in delayed‐release proton‐pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005, 22(Suppl. 3): 10–19.

6. Chey W.D., Mody R.R., Izat E. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement? Dig Dis Sci. 2010; 55(12): 3415-22.

7. Dean B.B., Gano A.D., Knight K., Ofman J.J., Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004; 2: 656–64.

8. Zhang J.X., Ji M.Y., Song J., Lei H.B., Qiu S., Wang J. et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013; 19(45): 8408-19.

9. Sachs G., Shin J.M., Howden C.W. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006; 23(Suppl 2): 2-8.

10. Miner P.J., Katz P.O., Chen Y., Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five‐way crossover study. Am J Gastroenterol. 2003; 98: 2616–20.

11. Fass R., Murthy U., Hayden C.W., Malagon I.B., Pulliam G., Wendel C., Kovacs T.O. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventionaldose lansoprazole therapy-a prospective, randomized, multi-centre study. Aliment Pharmacol Ther. 2000; 14(12): 1595-603.

12. Zhang H., Yang Z., Ni Z., Shi Y. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of dastroesophageal reflux disease. Gastroenterol Res Pract. 2013; Article ID 9865963.

13. Fujiwara Y., Arakawa T., Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol. 2012; 47(7): 760-9.

14. Nzeako U.C., Murray J.A. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther. 2002; 16: 1309–16.

15. Белоусов Ю.Б., Леонова М.В. Лекарственные формы с модифицированным высвобождением и системы доставки лекарств: особенности фармакокинетики и клиническая эффективность. М.: «Литтерра», 2011: 440-444.

16. Frye J.W., Peura D.A. Managing gastroesophageal reflux disease – comparative efficacy and outcomes of dexlansoprazole MR. Ther Clin Risk Manag. 2015; 11: 1649–56.

17. Katsuki H., Yagi H., Arimori K., Nakamura C., Nakano M., Katafuchi S. et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res. 1996, 13: 611–5.

18. Metz D.C., Vakily M., Dixit T., Mulford D. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009; 29: 928–37.

19. Vakily M., Zhang W., Wu J., Atkinson S., Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009; 25: 627–38.

20. Wu J., Vakily M., Witt G., Mulford D. TAK-390MR vs. lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher%-time pH>4. Am J Gastroenterol. 2007; 102(suppl 2): S124 (abstract).

21. Lee R.D., Mulford D., Wu J., Atkinson S.N. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a dual delayed release proton pump inhibitor. Aliment Pharmacol Ther. 2010; 31: 1001-11.

22. Sharma P., Shaheen N.J., Perez M.C., Pilmer B.L., Lee M., Atkinson S.N., Peura D. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel delayed-release formulation – results from two randomized controlled studies. Aliment Pharmacol Ther. 2009; 29: 731-41.

23. Fass R., Chey W.D., Zakko S.F, Andhivarothai N., Palmer R.N., Perez M.C., Atkinson S.N. Clinical trial: the effect of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009; 29: 1261-72.

24. Farup C., Kleinman L., Sloan S., Ganoczy D., Chee E., Lee C., Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001; 161: 45–52 .

25. Mody R., Bolge S.C., Kannan H., Fass R. Effects of gastroesophageal reflux disease on sleep and outcomes. Clin Gastroenterol Hepatol. 2009; 7: 953–9.

26. Fass R., Johnson D.A., Orr W.C., Han C., Mody R., Stern K.N. et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol. 2011; 106: 421-31.

27. Fass R., Inadomi J., Han G., Mody R., O’Neil J., Perez M.C. Maintenance of heartburn relief after stepdown from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012; 10: 247-63.

28. Dickman R., Maradey-Romero C., Gingold-Belfer R., Fass R.. Unmet needs in the treatment of gastroesophageal reflux disease. J Neurogastroenterol Motil. 2015; 21: 309–19.

29. Metz D.C., Howden C.W., Perez M.C., Larsen L., O’Neil J., Atkinson S.N. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment Pharmacol Ther. 2009; 29: 742–54.

30. Peura D.A., Metz D.C., Dabholkar A.H., Paris M.M., Yu P., Atkinson S.N. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment Pharmacol Ther. 2009; 30: 1010-21.

31. Zhang W., Wu J., Atkinson S.N. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol. 2009; 49(4): 444–454.

32. Ивашкин В.Т., Маев И.В., Трухманов А.С., Баранская Е.К., Дронова О.Б., Зайратьянц О.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерол. гепатол. колопроктол. 2017; 27(4): 75-95.